Telaprevir (TVR) is an orally available protease inhibitor of the hepatitis C virus that in association with pegylated interferon and ribavirin (PR) was shown to improve the rates of sustained virological response and potentially reduce treatment duration in adult patients with chronic hepatitis C genotype. Despite its robust activity in both treatment-naïve and experienced patients, the addition of TVR to PR is counterbalanced by increased costs and adverse events; moreover, there are still areas of uncertainty that regard treatment of patients with advanced liver disease, the role of patient stratification by genetic predictors, and the use/need for a lead-in phase with PR. Since TVR regimens have been associated with the risk of viral mutants that may cause treatment failure and jeopardize future therapeutic strategies with direct-acting antiviral agents, early stopping rules have been designed to protect patients with a poor virological response to TVR regimens against such a risk. © 2012 D'Ambrosio et al, publisher and licensee Dove Medical Press Ltd.

Treatment of experienced and naïve patients with hepatitis C : focus on telaprevir / R. D'Ambrosio, A. Aghemo, M. Colombo. - In: BIOLOGICS. - ISSN 1177-5475. - 6(2012), pp. 363-370. [10.2147/BTT.S20673]

Treatment of experienced and naïve patients with hepatitis C : focus on telaprevir

R. D'Ambrosio
Primo
;
A. Aghemo
Secondo
;
M. Colombo
2012

Abstract

Telaprevir (TVR) is an orally available protease inhibitor of the hepatitis C virus that in association with pegylated interferon and ribavirin (PR) was shown to improve the rates of sustained virological response and potentially reduce treatment duration in adult patients with chronic hepatitis C genotype. Despite its robust activity in both treatment-naïve and experienced patients, the addition of TVR to PR is counterbalanced by increased costs and adverse events; moreover, there are still areas of uncertainty that regard treatment of patients with advanced liver disease, the role of patient stratification by genetic predictors, and the use/need for a lead-in phase with PR. Since TVR regimens have been associated with the risk of viral mutants that may cause treatment failure and jeopardize future therapeutic strategies with direct-acting antiviral agents, early stopping rules have been designed to protect patients with a poor virological response to TVR regimens against such a risk. © 2012 D'Ambrosio et al, publisher and licensee Dove Medical Press Ltd.
Pegylated interferon; Protease inhibitor; Ribavirin; Oncology; Immunology and Allergy; Pharmacology (medical); Gastroenterology; Rheumatology
Settore MED/12 - Gastroenterologia
Article (author)
File in questo prodotto:
File Dimensione Formato  
BTT-20673-treatment-experienced-and-naive-patients-with-hepatitis-c--f_101712.pdf

accesso riservato

Tipologia: Publisher's version/PDF
Dimensione 186.92 kB
Formato Adobe PDF
186.92 kB Adobe PDF   Visualizza/Apri   Richiedi una copia
Pubblicazioni consigliate

Caricamento pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/2434/259767
Citazioni
  • ???jsp.display-item.citation.pmc??? 0
  • Scopus 2
  • ???jsp.display-item.citation.isi??? ND
social impact